A Nonprofit Drugmaker Is Taking Aim at Insulin Price Gouging

by | May 9, 2022 | Progress & Solutions, Fact Heroes

Photo by David Moruzzi

A Nonprofit Drugmaker Is Taking Aim at Insulin Price Gouging

by | May 9, 2022 | Progress & Solutions, Fact Heroes

Photo by David Moruzzi
Civica Rx, a nonprofit that manufactures generic drugs, is trying to help solve the problem of rampant insulin price gouging and profiteering by major drug makers.

Doctors have been treating diabetes with insulin since 1922. A century later, about 1 in 5 of the 37 million Americans living with diabetes take this medication – a hormone that helps cells absorb sugar from the blood.

This medication helps avert a host of medical problems including heart disease, kidney disease and stroke. Some 1.6 million Americans living with Type 1 diabetes, a condition in which people don’t produce any insulin, depend on it for their survival. So do millions more people with Type 2 diabetes – a condition in which the body doesn’t make enough insulin.

But an estimated 1 in 4 of the Americans who need it have so much trouble affording this lifesaving medication that they skimp on doses because insulin prices have been skyrocketing for years. For example, the full cost – not counting insurance coverage – of about one month’s worth of a commonly used kind of insulin called glargine has nearly tripled from US$99 in 2010 to $284 in 2022.

The exact amount Americans pay for insulin varies quite widely, depending on their insurance coverage and which version of the medication they’re prescribed.

Civica Rx, a nonprofit that manufactures generic drugs, is trying to help solve this problem. It’s planning to produce generic insulin for no more than $30 for a month’s worth of the drug at a factory being built in Petersburg, Virginia. Eventually the drugmaker intends to sell all three of the most popular kinds of insulin, starting in 2024 with glargine.

Based on my research regarding the pharmaceutical industry and my work as a doctor who treats patients with diabetes, I believe this effort, announced in March 2022, may greatly increase access to insulin for hundreds of thousands of people who need but can’t currently afford it.

Generic Insulin Competition Is Limited

Americans rely on robust competition from low-cost generic drugs to make pharmaceutical products more affordable. This system has historically been more successful with blockbuster drugs like atorvastatin – a cholesterol-controlling drug better known by the brand name Lipitor – and azithromycin – an antibiotic sold under the brand name Zithromax.

Unfortunately, this system has failed to restrain increases in insulin prices, which are far higher in the United States than other countries.

One reason this has been the case has to do with the fact that insulin is a biologic drug, meaning that it’s produced using DNA technology by living organisms. Biologic drugs are harder to manufacture and are regulated by the Food and Drug Administration in a different manner than more conventional drugs.

Seeing Reasons For Optimism

I’m excited about this initiative because it promises to increase access to all people who require insulin in the U.S., regardless of insurance status or where they buy medications.

One reason is that Civica Rx is a nonprofit that will be more able than private-sector drugmakers to put the interests of those who pay for insulin – patients and health insurers – ahead of investors’.

Another is its pricing strategy. Civica Rx plans to charge only about 20% of the list prices for brand-name insulin products. Walmart and some other big-box retailers already sell insulin at a discount, but their prices are still higher than what the nonprofit plans to charge.

And findings from my own research suggest that intellectual property protections will not likely be a substantial barrier to Civica’s efforts.

I’m also optimistic because of support from large insurers like Anthem and Blue Cross Blue Shield Association for this effort. It’s reassuring that Civica Rx’s leadership includes many people with decades of experience in the pharmaceutical industry and in health policy.

But I see some reasons to be less optimistic.

First, there have been prior attempts to manufacture generic insulin in the U.S. None have succeeded.

Another possibility is that brand-name insulin manufacturers may try to push doctors to prescribe newer patent-protected versions of insulin, which would be harder for Civica Rx to market as a generic – at least initially.

Success is far from guaranteed, given that the established players all have a strong financial interest in seeing Civica’s efforts fail.

Lawmakers Are Taking Action

Several state legislatures have also tried to deal with this problem. Some have enacted laws mandating drug price transparency and provided funds to guarantee emergency access to insulin.

Members of Congress – from left, Rep. Dan Kildee, D-Mich.; House Majority Whip James Clyburn, D-S.C.; Rep. Angie Craig, D-Minn.; and Rep. Lucy McBath, Ga. – express support for capping insulin prices at $35 a month or less in March 2022. AP Photo/J. Scott Applewhite

But to date these assorted responses have failed to lower prices for brand-name insulin products, although I think it’s possible that prices would have risen faster without them.

Congress is also responding.

Four weeks after Civica Rx announced its plans to produce insulin at well below current prices, the U.S. House of Representatives passed a bill that would limit insulin copays to $35 for insured patients. This measure was also in President Joe Biden’s stalled Build Back Better spending plan.

The House bill would leave out many patients – most notably the uninsured. But this measure would also mark a positive step should the Senate follow suit.

People living with insulin-dependent diabetes have been waiting a long time for someone to do something to make it more affordable. It looks like that time may finally be arriving.The Conversation

Republished with permission from The Conversation, by Jing Luo, Assistant Professor of Medicine, University of Pittsburgh Health Sciences

The Conversation

The Conversation

The Conversation is a nonprofit, independent news organization dedicated to unlocking the knowledge of experts for the public good. We publish trustworthy and informative articles written by academic experts for the general public and edited by our team of journalists.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Follow Us

Related Articles

Nov 27 2022

DOJ Opens Investigation Into Rent-Setting Tech Company RealPage

The DOJ will examine whether RealPage helped landlords coordinate rent increases. Questions also swirl around a 2017 merger deal with its largest competitor.
Nov 17 2022

Farmers in the Midwest Are Turning to Solar to Boost Profits

As adoption of solar projects on farmland climbs, many farmers and industry players are looking for ways to add solar to agricultural production without halting crop...
Nov 15 2022

Cultivating Human Farming Practices and Wisdom From Ants

Agricultural pest management has focused on genetically engineering crops to produce their own pesticides, but the lesson from 55 million years of ant agriculture is to...
Nov 11 2022

California Takes Action Against Manufacturers of ‘Forever Chemicals’

Forever chemicals, found in drinking water, soil, wildlife, and people across the country, have been linked to health problems, including multiple types of cancer,...
Nov 08 2022

Election Officials Are Overworked, Underpaid, Feeling Pressured and Under Threat

Election officials have little control over election rules. They’re not lawmakers. But they are under enormous demand, poorly paid and sometimes have their lives...
Nov 04 2022

Election Officials Are Ready and Cautiously Optimistic for the Midterms

Recent polls indicate Americans are increasingly confident about the electoral process. But state and local administrators aren’t taking any chances and are sharing...
man beside boy holding red and white rally signage
Nov 03 2022

Democracy Itself Is on the Ballot in These Midterms

Former president’s “Big Lie” that he won the 2020 election has fueled the dangerous rise in political violence and voter intimidation over the past...
Oct 02 2022

When the Power Grid Goes Out, Could Solar and Batteries Power Your Home?

Researchers at Lawrence Berkley Labs found that even a modest system of solar plus one battery can power critical loads in a home for days at a time, practically...
Oct 01 2022

Hurricane Ian and Questions of Risk and Resilience

One western Florida community celebrated the success of a program to restore what Hurricane Michael took from it, others braced for Hurricane Ian, a storm projected to...
Sep 27 2022

What Happens When Hurricane Hunters Fly Through Storms to Get the Forecasts We Rely On

Satellites can offer forecasters a basic view, but hurricane hunters flying into the storm itself can really pick the hurricane apart.
Subscribe for Updates!

Subscribe for Updates!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Pin It on Pinterest

Share This